Key result
Add-on Ivabradine in patients with dilated cardiomyopathy significantly reduced heart rate (-32.2% vs -19.3%, p=0.001) and improved LVEF (28.8 vs 27.2, p=0.01) compared to standard therapy.
Why the study?
Does the addition of ivabradine to standard therapy improve echocardiographic parameters and clinical symptoms in patients with dilated cardiomyopathy and a baseline heart rate >70/min?
RCT (n=125)
Does the addition of ivabradine to standard therapy improve echocardiographic parameters and clinical symptoms in patients with dilated cardiomyopathy and a baseline heart rate >70/min?
Absolute Event Rate: 28.8% vs 27.2%
p-value: p=0.01
The addition of ivabradine to standard therapy in patients with dilated cardiomyopathy and a resting heart rate >70 bpm significantly improves left ventricular systolic function, structural echocardiographic parameters, and patient-reported quality of life.
No takes yet. Share an insight, caveat, or question.
Supports adjunctive heart rate control for symptomatic relief in dilated cardiomyopathy; extends established heart failure.
Raja et al. (2017) conducted an RCT in Dilated cardiomyopathy with symptomatic heart failure (n=125). Ivabradine vs. standard therapy (beta blockers, ACEI, diuretics) was evaluated on LVEF (p=0.01). Add-on Ivabradine in patients with dilated cardiomyopathy significantly reduced heart rate (-32.2% vs -19.3%, p=0.001) and improved LVEF (28.8 vs 27.2, p=0.01) compared to standard therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: